Protective Response to Subunit Vaccination Against Intranasal and Challenge

Overview

Journal Procedia Vaccinol

Publisher Elsevier

Date 2014 Jan 1

PMID 24379895

Citations 28

Authors

Gregory C Whitlock

Arpaporn Deeraksa

Omar Qazi

Barbara M Judy

Katherine Taylor

Katie L Propst

Angie J Duffy

Kate Johnson

G Barrie Kitto

Katherine A Brown

Steven W Dow

Alfredo G Torres

D Mark Estes

Affiliations

Soon will be listed here.

Abstract

and are Gram-negative pathogenic bacteria, responsible for the diseases glanders and melioidosis, respectively. Furthermore, there is currently no vaccine available against these species. In this study, we aimed to identify protective proteins against these pathogens. Immunization with recombinant Hcp1 (type VI secreted/structural protein), BimA (autotransporter protein), BopA (type III secreted protein), and LolC (ABC transporter protein) generated significant protection against lethal inhaled ATCC23344 and 1026b challenge. Immunization with BopA elicited the greatest protective activity, resulting in 100% and 60% survival against and challenge, respectively. Moreover, sera from recovered mice demonstrated reactivity with the recombinant proteins. Dendritic cells stimulated with each of the different recombinant proteins showed distinct cytokine patterns. In addition, T cells from immunized mice produced IFN-γ following re-stimulation. These results indicated therefore that it was possible to elicit cross-protective immunity against both and by vaccinating animals with one or more novel recombinant proteins identified in .

Citing Articles

Genetic variation of hemolysin co-regulated protein 1 affects the immunogenicity and pathogenicity of Burkholderia pseudomallei.

Tandhavanant S, Yimthin T, Sengyee S, Charoenwattanasatien R, Lebedev A, Lafontaine E PLoS Negl Trop Dis. 2025; 19(1):e0012758.

PMID: 39761280 PMC: 11737846. DOI: 10.1371/journal.pntd.0012758.

Surface-Exposed Protein Moieties of J2315 in Microaerophilic and Aerobic Conditions.

Seixas A, Silva C, Marques J, Mateus P, Rodriguez-Ortega M, Feliciano J Vaccines (Basel). 2024; 12(4).

PMID: 38675780 PMC: 11054960. DOI: 10.3390/vaccines12040398.

Complex Subunit and Glycoconjugate Vaccines and Their Potential to Elicit Cross-Protection to Complex.

Badten A, Torres A Vaccines (Basel). 2024; 12(3).

PMID: 38543947 PMC: 10975474. DOI: 10.3390/vaccines12030313.

LVS Δ-vectored multiantigenic melioidosis vaccines protect against lethal respiratory challenge in highly sensitive BALB/c mice.

Tullius M, Bowen R, Back P, Maslesa-Galic S, Nava S, Horwitz M mBio. 2024; 15(4):e0018624.

PMID: 38511933 PMC: 11005352. DOI: 10.1128/mbio.00186-24.

Hcp1-loaded staphylococcal membrane vesicle vaccine protects against acute melioidosis.

Zhu K, Li G, Li J, Zheng M, Peng X, Rao Y Front Immunol. 2023; 13:1089225.

PMID: 36618368 PMC: 9822774. DOI: 10.3389/fimmu.2022.1089225.

References

Stone R . Infectious disease. Racing to defuse a bacterial time bomb. Science. 2007; 317(5841):1022-4. DOI: 10.1126/science.317.5841.1022. View

Nelson M, Prior J, Lever M, Jones H, Atkins T, Titball R . Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol. 2004; 53(Pt 12):1177-1182. DOI: 10.1099/jmm.0.45766-0. View

Krieg A . Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5(6):471-84. DOI: 10.1038/nrd2059. View

Bendtsen J, Nielsen H, von Heijne G, Brunak S . Improved prediction of signal peptides: SignalP 3.0. J Mol Biol. 2004; 340(4):783-95. DOI: 10.1016/j.jmb.2004.05.028. View

Brett P, Mah D, Woods D . Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect Immun. 1994; 62(5):1914-9. PMC: 186440. DOI: 10.1128/iai.62.5.1914-1919.1994. View

Srinivasan A, Kraus C, Deshazer D, Becker P, Dick J, Spacek L . Glanders in a military research microbiologist. N Engl J Med. 2001; 345(4):256-8. DOI: 10.1056/NEJM200107263450404. View

Waag D, McCluskie M, Zhang N, Krieg A . A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun. 2006; 74(3):1944-8. PMC: 1418646. DOI: 10.1128/IAI.74.3.1944-1948.2006. View

Whitlock G, Estes D, Torres A . Glanders: off to the races with Burkholderia mallei. FEMS Microbiol Lett. 2007; 277(2):115-22. DOI: 10.1111/j.1574-6968.2007.00949.x. View

Dance D . Melioidosis: the tip of the iceberg?. Clin Microbiol Rev. 1991; 4(1):52-60. PMC: 358178. DOI: 10.1128/CMR.4.1.52. View

10.

KROGH A, Larsson B, von Heijne G, Sonnhammer E . Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001; 305(3):567-80. DOI: 10.1006/jmbi.2000.4315. View

11.

Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A . Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol. 2006; 176(12):7335-45. DOI: 10.4049/jimmunol.176.12.7335. View

12.

Utaisincharoen P, Kespichayawattana W, Anuntagool N, Chaisuriya P, Pichyangkul S, Krieg A . CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol. 2003; 132(1):70-5. PMC: 1808663. DOI: 10.1046/j.1365-2249.2003.02107.x. View

13.

Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, Dow S . Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun. 2009; 77(4):1579-88. PMC: 2663177. DOI: 10.1128/IAI.01384-08. View

14.

Bryan L, Wong S, Woods D, Dance D, Chaowagul W . Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can J Infect Dis. 2012; 5(4):170-8. PMC: 3250846. DOI: 10.1155/1994/856850. View

15.

Harland D, Chu K, Haque A, Nelson M, Walker N, Sarkar-Tyson M . Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun. 2007; 75(8):4173-80. PMC: 1951986. DOI: 10.1128/IAI.00404-07. View

16.

Kelley L, Sternberg M . Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc. 2009; 4(3):363-71. DOI: 10.1038/nprot.2009.2. View

17.

Brett P, Woods D . Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun. 1996; 64(7):2824-8. PMC: 174148. DOI: 10.1128/iai.64.7.2824-2828.1996. View

18.

Horn J . Bacterial agents used for bioterrorism. Surg Infect (Larchmt). 2003; 4(3):281-7. DOI: 10.1089/109629603322419625. View

19.

Neubauer H, Sprague L, Zacharia R, Tomaso H, Al Dahouk S, Wernery R . Serodiagnosis of Burkholderia mallei infections in horses: state-of-the-art and perspectives. J Vet Med B Infect Dis Vet Public Health. 2005; 52(5):201-5. DOI: 10.1111/j.1439-0450.2005.00855.x. View

20.

Whitlock G, Estes D, Young G, Young B, Torres A . Construction of a reporter system to study Burkholderia mallei type III secretion and identification of the BopA effector protein function in intracellular survival. Trans R Soc Trop Med Hyg. 2009; 102 Suppl 1:S127-33. DOI: 10.1016/S0035-9203(08)70029-4. View